Our study showed that SMARCC2 could significantly inhibit the PI3K/AKT pathway in glioblastoma cell lines by targeting DKK1, therefore, targeting DKK1 degraders and PI3K/AKT pathway inhibitors may be a new idea for the clinical treatment of glioblastoma. This evidence concerns the gene DKK1 and glioblastoma.